Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hmm, so how much is on the line if it drops below $5? How much do you think someone would be willing to lose to keep it there?
Will it hold $5?
Athanasios Skarpelos Net Worth
The estimated Net Worth of Athanasios Skarpelos is at least $40.5 Million dollars as of 29 June 2009. Mr. Skarpelos owns over 841,668 units of Anavex Life Sciences stock worth over $35,310,618 and over the last 13 years he sold AVXL stock worth over $5,123,753. In addition, he makes $93,871 as Independent Director at Anavex Life Sciences.
wallmine
Skarpelos?
Thanks Xena about the tab note.
That is my point. This is a "casino" stock. My post reflects the market directly. It is a historical record about AVXL, nothing more.
In essence, the market has looked at the information that Anavex has provided thus far as insignificant. The market is not pricing in new trials or data.
Date MC OS
10/28/2015 294.14M 31.13M
12/29/2015 217.30M 34.60M
2/5/2016 160.79M 34.65M
5/11/2016 156.77M 35.71M
8/11/2016 107.85M 35.71M
12/12/2016 193.30M 39.61M
2/7/2017 219.33M 41.07M
5/10/2017 247.02M 41.38M
8/7/2017 166.16M 42.17M
12/8/2017 163.17M 44.22M
2/7/2018 118.12M 44.57M
5/10/2018 93.34M 44.66M
8/9/2018 128.57M 45.43M
12/12/2018 98.76M 46.59M
1/22/2019 80.65M 46.89M
5/8/2019 149.80M 49.12M
8/7/2019 130.05M 52.65M
12/12/2019 136.94M 56.12M
2/6/2020 243.46M 58.66M
5/7/2020 195.94M 58.66M
8/4/2020 288.91M 60.19M
I still consider AVXL a "casino" investment with higher odds of success. So far our increase in Market Cap has been fairly eroded with dilution. I've seen this company go from about a 10 million float to now somewhere around 60 million. Anavex needs capital to keep moving forward, so it is a necessary evil.
I don't in any way consider this a winning/successful company, Anavex has not made it to market and generates no revenue, that is a risk. Their expanding pipeline and pursuit of application helps to derisk though. In general, I think the company is undervalued (based on my own risk profile), thus my investment. I do share this stock with others and always caution to not invest more than you are comfortable losing.
How about we, the Anavex "Army", "fight" with science. Certainly hype and hope could boost the share price, but "fighting" against the "Cabal" before crossing the finish line... Hats off to the victor left standing at the finish line when the dust clears. Agora certainly tried to "fight" for hope and dreams, what did that result in and what were the motivations?
These should have been defined at the time of trial design, the trial protocol and statistical analysis plan. Sure analysis of complex information can take time, especially for large trials. Material doesn't even have to to be the trial endpoints only.
Submission of information for statutory requirements of FDAAA vs SEC disclosure are 2 different things.
Here's another summary:insert-text-here
$4.90 looking good. More news eventually.
Hmm, that reads for publishing data... not releasing material information. What is SEC guidance?
This was interesting:JDSUPRA
Churning, which direction next.
About to go under $5. If you were looking to buy back, they probably helped you out.
In this case you would be fortunate.
No issues. $5.41 now.
Yay! Glad to see this.
That's the crux. Either the data that we have is good enough to stand alone, or I agree with you. Top line data should be easy to package based on the statistical analysis plan. The thing that takes time is analyzing the information to speak about how the data will be used in the future. The data should speak for itself, fact based, and describe the objective observations of the trial. How they want to use the data is subjective.
I agree! If results are as astounding as some suggest, we should be on the agenda, and release all top-line data!
In my non-expert opinion, these were not great results without more information. I think there are too many statistical variables to understand what the results represent. I am not questioning if the results were what they were in these specific measures, only that without all of the information, the data presented has no context.
There have been clinical trials that show great results in some aspect, but there are other aspects that defeat the purpose of the same drug. Some companies are not able to isolate the observed benefit from those that are negative. When something is not presented in full context it leaves question about what was not revealed, and the risk remains. Hope and trust in the unknown are not a good investment strategy, at least in my opinion.
I agree in the excitement. There was some very encouraging data. The other noise is what is bothering me. Especially in light of a partial data release.
This is exactly what you want from a CEO...:
Missling and gang knew already and that was most likely the chant in the office while holding hands and jumping around like a bunch of school girls.
I've heard the same from other world class experts only to be refuted from other world class experts. I'm no expert trader, but I would like to know where the top line data is. I know enough to know about Enrons and Martha Stewarts. Market sentiment so far has been negative. Like it or not.
This has been a flop. Why? Self-expert traders. Wake up.
They did? This is what I read...
Anavex is planning a pivotal trial of ANAVEX®2-73 (blarcamesine) in Parkinson’s disease dementia after submitting the results of the study to the FDA to obtain regulatory guidance.
They should have submitted a statistical analysis plan in conjunction with the trial protocol to define when trial endpoints are met. Since this is a proof of concept trial, it is not expected that all endpoints will be met. Lack of top line data and uncertainty on the outcome of all trial end points leaves much to question. What information they did present is encouraging.
This feels more like a movie trailer then release of trial results. Fall 2020 Anavex releases partial trial results that will leave you on the edge of your seats wondering, what did I just watch and when is the rest of the movie coming out?
This is shrinking fast.
Applause!!!
Agreed. They went off half cocked and it plays into the selective spin of data. Either this was amateur move of excitement or lack of the right people to manage data release, but that also depends on what information they are actually sitting on.
There were primary endpoints defined, so there were expectations. The trial was designed with a very specific set of criteria to determine if the end points were met. People invest based on this information, and expectation that they will know the results of the trial when complete.
That is my question as well. What material information?
If Anavex knows the trial failed per the criteria established for trial design, that is material.
Are investors able to see the statistical analysis plan as presented for trial design?
Anavex stated the CTAD presentation would be focused on AD info.
Primary Outcome Measures:
Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention [ Time Frame: 14 weeks ]
Change from Baseline to End of Treatment in Continuity of Attention as measured by Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention test.
Anavex PR:
The results show clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis.
I think your first question should be more direct: Were the primary endpoints met for trial NCT03774459?
Great. Then I can make note they are holding on to material information until then. It will be interesting to see how the stock trades in the mean time.
Then an investor conference call and PR is in order.
No, but it did say results are clinically meaningful. It is Anavex's responsibility to demonstrate this effect.
They also did not say the primary end point was not met. In the absence of either of these terms the information presented would have to provide substantial evidence as to the results of the trial. If Anavex knows the primary end point was not met, they are withholding yet more material information, and misleading investors to believe the primary end point results were: clinically meaningful, dose-dependent, and statistically significant. If that is not a definition for primary end point was met, what is?
If they don't know what they caught, and released the initial PR that they did, they now have alot more to worry about.
Just like the remaining data was failed to be mentioned by Anavex?
I don't recall Anavex presenting the information in the manner you describe. They failed investors if they withheld or overlooked the information as you describe. A PR with information not related to CTAD was needed, if so.
This looks intriguing... side thought, where is the rest of the data?
I agree. It sends the right message, and it shouldn't come with an increase in salary.
Which provides no information to the material nature of the data. One could speculate that the supplemental data is good or bad or neutral. Not all material information has been released. All they have stated is there is supplementary data.
I'm encouraged by what they presented. I'm glad they will be releasing this at some point, but I think in the excitement of trying to release information as soon as possible at CTAD they left more doubt and question.
Which provides no information to the material nature of the data. One could speculate that the supplemental data is good or bad or neutral. Not all material information has been released. All they have stated is there us supplementary data.